Translational Pharmacokinetic‐Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI ‐6148 for the Treatment of Cutaneous Leishmaniasis

Documenti analoghi

• Population Pharmacokinetic–Pharmacodynamic Modeling of Granulocyte Colony‐Stimulating Factor to Optimize Dosing and Timing for CD34+ Cell Harvesting
  di: Xu Jiang, et al.
  Pubblicazione: (2025)
• Pharmacokinetic‐Pharmacodynamic Model of Paclitaxel‐Induced Peripheral Neuropathy
  di: Yuchen Sun, et al.
  Pubblicazione: (2025)
• Population Pharmacokinetic and Pharmacodynamic Prediction for Tebipenem Pivoxil Treatment of Pediatric Shigellosis
  di: Cindy X. Zhang, et al.
  Pubblicazione: (2025)
• Effect of E7777 Immunogenicity on Pharmacokinetics, Efficacy, and Safety in Adult Patients With Relapsed or Refractory Cutaneous T‐Cell Lymphoma
  di: Theingi M. Thway, et al.
  Pubblicazione: (2025)
• Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants
  di: Jean‐Yves Gillon, et al.
  Pubblicazione: (2025)